Drug Update · Endocrinology

FDA Approves Tirzepatide for Obesity: 20.9% Weight Loss in SURMOUNT-1

July 15, 2026

SURMOUNT-1 enrollment

2,539 adults [1]

Mean % weight change at week 72 (15 mg)

-20.9% versus -3.1% placebo [1]

≥5% weight loss rate (15 mg)

91% versus 35% placebo [1]

FDA original approval date

2023-11-08 [12]

Clinical Perspective

Endocrinologists, obesity medicine specialists, and primary-care clinicians managing adults with obesity or adults with overweight plus at least one weight-related comorbidity are affected by this approval ^[2]^[1]. The SURMOUNT-1 data support use of tirzepatide to achieve substantial mean weight reductions at week 72 compared with placebo, including high proportions achieving ≥5% and ≥20% weight loss in the 10 mg and 15 mg groups ^[1]. How clinicians should position tirzepatide among other pharmacologic options for chronic weight management in individual patients and in head-to-head comparisons remains an open question?

Dr. Amit Desai · Endocrinology

The FDA approved tirzepatide (ZEPBOUND) for reduction of excess body weight and long-term weight maintenance in adults with obesity or adults with overweight with at least one weight-related comorbid condition on 2023-11-08 based on the SURMOUNT-1 trial showing mean percentage weight changes at week 72 of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo ^[1]^[2]. Clinicians should consult current prescribing information for full dosing guidance. The approval and label specify initiation and escalation and maintenance dosing options consistent with the trial program ^[2].

Clinical Context

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist; the molecule engages both receptors and includes a fatty diacid enabling albumin binding and prolonged half-life as described in the label ^[2]. The drug is marketed as ZEPBOUND; Eli Lilly is listed among investigators and contributors in the SURMOUNT-1 report ^[1]. The FDA approval covers use in adults with obesity or adults with overweight plus at least one weight-related comorbidity to reduce excess body weight and maintain weight reduction long term, with the label describing the recommended escalation and maintenance dosages evaluated in the phase 3 program ^[2]. The key randomized evidence supporting the approval is the SURMOUNT-1 phase 3 trial ^[1].

Key Findings

The SURMOUNT-1 trial (phase 3, randomized, double-blind) evaluated once-weekly subcutaneous tirzepatide (5 mg, 10 mg, 15 mg) versus placebo in adults without diabetes and showed mean percentage changes in body weight at week 72 of -15.0% with 5 mg, -19.5% with 10 mg, and -20.9% with 15 mg versus -3.1% with placebo (P<0.001 for all comparisons) ^[1].
Clinicians should consult current prescribing information for full dosing guidance.
In SURMOUNT-1 the percentages of participants achieving ≥5% weight reduction at week 72 were 85% with 5 mg, 89% with 10 mg, and 91% with 15 mg versus 35% with placebo; weight reductions of ≥20% were reported in 50% (10 mg) and 57% (15 mg) versus 3% with placebo ^[1].
The trial enrolled 2,539 adults (BMI ≥30 or ≥27 with at least one weight-related complication, excluding diabetes), used a 1:1:1:1 randomization, and included a 20-week dose-escalation period within the 72-week treatment duration; coprimary endpoints were percentage change in weight from baseline and the proportion achieving ≥5% weight reduction ^[1].

Safety & Tolerability

The most common adverse events reported with tirzepatide in SURMOUNT-1 were gastrointestinal in nature; most were mild to moderate in severity and occurred primarily during dose escalation ^[1].
Adverse events caused treatment discontinuation in 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) of tirzepatide-treated participants versus 2.6% of participants receiving placebo in SURMOUNT-1 ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Study Design

The FDA approval relied principally on SURMOUNT-1, a phase 3, double-blind, randomized, placebo-controlled trial (NCT04184622) that randomized 2,539 adults without diabetes in a 1:1:1:1 ratio to once-weekly subcutaneous tirzepatide 5 mg, 10 mg, or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period; coprimary endpoints were percentage change in body weight and the proportion with ≥5% weight reduction at week 72 ^[1]^[2]. Clinicians should consult current prescribing information for full dosing guidance. The FDA prescribing information and approval record cite the trial results when describing the indication and dosing evaluated ^[2].

FAQ

Q1 What is tirzepatide (ZEPBOUND) approved for?

Tirzepatide (ZEPBOUND) is approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or in adults with overweight who have at least one weight-related comorbid condition. The FDA label also notes an indication to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Q2 How does tirzepatide work?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The label describes binding and activation of both GIP and GLP-1 receptors; the molecule contains a C20 fatty diacid that enables albumin binding and prolongs the half-life, and nonclinical data show distribution to brain regions involved in appetite regulation.

Q3 What is the recommended dose of tirzepatide (ZEPBOUND)?

The FDA labeling describes an initiation dose of 2.5 mg subcutaneously once weekly for 4 weeks for treatment initiation, with escalation in 2.5 mg increments after at least 4 weeks until a recommended maintenance dosage is achieved. Maintenance dosages evaluated for weight reduction and long-term maintenance include 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly; the maximum recommended dosage is 15 mg once weekly. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of tirzepatide?

In SURMOUNT-1 the most common adverse events were gastrointestinal and were mostly mild to moderate in severity, occurring primarily during dose escalation. Adverse events led to treatment discontinuation in 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) of tirzepatide recipients versus 2.6% of placebo recipients in that trial.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Tirzepatide for Obesity: 20.9% Weight Loss in SURMOUNT-1

FDA Approves Tirzepatide for Obesity: 20.9% Weight Loss in SURMOUNT-1

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

FDA Approves Insulin Icodec (Awiqli) for Type 2 Diabetes: 0.22% HbA1c Reduction in ONWARDS 3

REDEFINE 1: CagriSema Achieves 20.4% Weight Loss in Adults

FDA Approves orforglipron for Obesity: 11.2% Weight Loss ATTAIN-1

Verified HCP Portal